Affymetrix Announces Fourth Quarter Total Revenue of Approximately $100 Million
January 08 2007 - 8:01AM
Business Wire
Affymetrix, Inc. (Nasdaq:AFFX) today announced that based on
preliminary financial data, the Company expects fourth quarter
total revenue of approximately $100 million. "During the fourth
quarter, we delivered important new products to customers and
announced several exciting commercial agreements," said Stephen
P.A. Fodor, chairman and chief executive officer. "It was a quarter
of solid performance." The Company will release fourth quarter and
year end 2006 operating results after the close of the market on
February 7, 2007. Company management will conduct its quarterly
conference call for fiscal year 2007 at 2:00 p.m. Pacific Time.
About Affymetrix Affymetrix scientists invented the world's first
high-density microarray in 1989 and began selling the first
commercial microarray in 1994. Since then, Affymetrix GeneChip�
technology has become the industry standard in molecular biology
research. Affymetrix technology is used by the world's top
pharmaceutical, diagnostic and biotechnology companies as well as
leading academic, government and not-for-profit research
institutes. More than 1,400 systems have been installed around the
world and more than 7,000 peer-reviewed papers have been published
using the technology. Affymetrix' patented photolithographic
manufacturing process provides the most information capacity
available today on an array, enabling researchers to use a
whole-genome approach to analyzing the relationship between
genetics and health. Affymetrix is headquartered in Santa Clara,
Calif., with manufacturing facilities in Sacramento, Calif.,
Bedford, Mass., and Singapore. The company maintains important
sales and marketing operations in Europe and Asia and has about
1,100 employees worldwide. For more information about Affymetrix,
please visit the company's website at www.affymetrix.com. All
statements in this press release that are not historical are
"forward-looking statements"�under the federal securities laws.
Such statements, including Affymetrix' expectations for its fourth
quarter and year end 2006 results, are subject to risks and
uncertainties that could cause actual results to differ materially
for Affymetrix from those projected, including but not limited to:
the preparation of financial statements for the fourth quarter and
full-year 2006; risks�related to�the Company's ability to achieve
and sustain higher levels of revenue and improved�gross margins and
operating income and reduced operating expenses (including risks
related to the outcome of the Company's previously announced
efforts to reduce expenses in the general and administrative
functions including the rationalization of the Company's
facilities); uncertainties relating to technological approaches,
manufacturing (including risks related to resolving any
manufacturing problems) and product development;�uncertainties
relating to changes in senior management personnel�and structure;
uncertainties related to cost and pricing of Affymetrix
products;�risks relating to dependence on collaborative partners;
uncertainties relating to sole source suppliers; uncertainties
relating to FDA and other regulatory approvals; competition; risks
relating to intellectual property of others and the uncertainties
of patent protection; and risks relating to intellectual property
and other litigation. These and other risk factors are discussed in
Affymetrix' Form 10-K/A for the year ended December 31, 2005 and
other SEC reports, including reports on Form 10-Q and Form 10-Q/A
for subsequent periods. Affymetrix expressly disclaims any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in Affymetrix' expectations or any change in
events, conditions, or circumstances on which any such statements
are based.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024